THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, April 18, 2023
AI and ML have the potential to transform the regulatory submissions process and improve the efficiency, accuracy, and quality of drug development.
FREMONT, CA: Artificial Intelligence (AI) and Machine Learning (ML) are rapidly changing the landscape of drug development and regulatory submissions. The pharmaceutical industry and regulatory agencies are increasingly adopting these technologies. AI and ML can streamline the regulatory submissions process and improve the quality of drug development.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Some ways AI and ML are being used in drug development and regulatory submissions include:
1. Predictive Modeling: AI and ML algorithms can build predictive models that can forecast potential risks and outcomes of clinical trials. These models can help optimise the trial design, identify potential safety issues, and improve the accuracy of endpoint predictions.
2. Data Mining: AI and ML analyse large data sets and extract meaningful insights. This help identifies potential safety issues, support decision-making, and optimise study design.
3. Natural Language Processing: By processing unstructured data, such as clinical trial reports, medical literature, and regulatory guidelines, AI and ML automate data extraction and standardisation in turn improving the efficiency of regulatory submissions.
4. Image Analysis: Medical picture analysis using AI and ML can spot patterns or abnormalities that could be signs of sickness or unfavourable outcomes. This enhances the precision of diagnoses, forecasts the results of treatments, and supports regulatory decision-making.
5. Pharmacovigilance: AI and ML help risk management by recognising adverse events early, improving signal detection, and discovering possible safety risks related to a medicine or medical device through the analysis of real-world data.
ML in pharmacometrics
Pharmacometrics represents linear processes by choosing a structural model, followed by random effects and covariates. The Genetic Algorithm (GA), a global search technique, can therefore be recommended as a superior option in the optimisation sector and produce a user-defined "search space" containing all the predicted candidate models reflecting all hypotheses to be evaluated. GA implementation employing NONMEM for parameter estimation is developing into a very reliable and economical method for developing population PKPD models.
Extrapolation of observed features and associated responses are possible with supervised machine learning. Additionally, ML aids in inferring correlations between responses and features and making predictions for fresh observations. In addition to the once-daily regimen used to construct the machine learning model, the model was able to predict patients' PD response with other dose regimens.
Nowadays, toxicities are predicted using quantitative structure-activity relationship (QSAR) models, which are based on chemical structural characteristics. Since there are numerous medications on the market with unclear modes of action, it is it has become a common practice to predict toxicities using artificial intelligence (AI), which employs complex algorithms. The QSAR model has recently been used to identify intricate relationships between chemical structures and toxicities.
The enhanced computing power and stronger algorithms developed in the last decade have led to a new discipline combining multiscale models and predictive algorithms based on artificial intelligence called computational pharmaceutics. With machine learning, large volumes of data can be analyzed systematically to find correlations or quantify the agreement of correlations, carrying characteristics across the scales, i.e., in the process of information homogenisation.
More in News